Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.55 |
| ▸ | ESR1 | P03372 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 7/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14981350 | 0.95 | MAPT (0.56) | MAPTKDM4EPOLBMAPK1KMT2A | |
| SCHEMBL777980 | 0.89 | MAPT (0.72) | MAPTKDM4EPOLBMAPK1KMT2A | |
| SCHEMBL14981364 | 0.88 | KMT2A (0.53) | MAPTKDM4EPOLBMAPK1KMT2A | |
| SCHEMBL14981340 | 0.87 | MAPT (0.48) | MAPTKDM4EPOLBMAPK1KMT2A | |
| SCHEMBL14981370 | 0.86 | KMT2A (0.49) | MAPTKDM4EPOLBMAPK1KMT2A | |
| SCHEMBL14884426 | 0.84 | KMT2A (0.62) | MAPTKDM4EKMT2AESR1MEN1 | |
| SCHEMBL14981328 | 0.84 | KMT2A (0.55) | MAPTKDM4EPOLBMAPK1KMT2A | |
| SCHEMBL777815 | 0.83 | KMT2A (0.58) | MAPTKMT2AESR1MEN1CASP3 | |
| SCHEMBL14981372 | 0.83 | KMT2A (0.46) | MAPTKDM4EPOLBMAPK1KMT2A | |
| SCHEMBL12268648 | 0.83 | KMT2A (0.60) | MAPTPOLBKMT2AESR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404794-B2 | Liquid crystal compositions | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404794-B2 | Liquid crystal compositions | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8344175-B2 | Liquid crystal compositions, polymer networks derived therefrom and process for making the same | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344175-B2 | Liquid crystal compositions, polymer networks derived therefrom and process for making the same | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120104316-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120104316-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120068116-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I.DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120068116-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I.DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071618-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071618-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2010144393-A2 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144411-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100308269-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308269-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308270-A1 | LIQUID CRYSTAL COMPOSTIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308270-A1 | LIQUID CRYSTAL COMPOSTIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308268-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308268-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308265-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308265-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100308265-A1 | LIQUID CRYSTAL COMPOSITIONS | CNOT9, AQP3, AQP1 | MAPT 23/4885KDM4E 2609/4885POLB 2082/4885 |
| US-20100308270-A1 | LIQUID CRYSTAL COMPOSTIONS | TTR, CNOT9, CNOT7 | MAPT 4/4885KDM4E 3395/4885POLB 1647/4885 |
| US-20120068116-A1 | LIQUID CRYSTAL COMPOSITIONS | AQP3, AQP1, NCAPD2 | MAPT 52/4885KDM4E 4027/4885POLB 2665/4885 |
| US-20120071618-A1 | LIQUID CRYSTAL COMPOSITIONS | CNOT9, AQP3, AQP1 | MAPT 23/4885KDM4E 2609/4885POLB 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.